Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents - A single blind randomized trial

References

• Gabutti G, Rota MC. Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health 2012; 9:4626-38; PMID:23330226; http://dx.doi.org/10.3390/ijerph9124626
   PubMed Web of Science ®Google Scholar
• Guiso N, Wirsing von Konig CH, Forsyth K, Tan T, Plotkin SA. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11–12 January 2010. Vaccine 2011; 29:1115-21; PMID:21168525; http://dx.doi.org/10.1016/j.vaccine.2010.12.010
   PubMedGoogle Scholar
• Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24:S58-61; PMID:15876927; http://dx.doi.org/10.1097/01.inf.0000160914.59160.41
   PubMedGoogle Scholar
• McCormack PL. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix(R)): a review of its properties and use as a single-dose booster immunization. Drugs 2012; 72:1765-91; PMID:22931522; http://dx.doi.org/10.2165/11209630-000000000-00000
   PubMed Web of Science ®Google Scholar
• Scott LJ, McCormack PL. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix((R))): a guide to its use as a single-dose booster immunization against pertussis. BioDrugs 2013; 27:75-81; PMID:23329401; http://dx.doi.org/10.1007/s40259-012-0009-y
   PubMed Web of Science ®Google Scholar
• Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010; 51:656-62; PMID:20704493; http://dx.doi.org/10.1086/655825
   PubMed Web of Science ®Google Scholar
• Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix((R))) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine 2011; 29:5932-9; PMID:21718738; http://dx.doi.org/10.1016/j.vaccine.2011.06.049
   PubMed Web of Science ®Google Scholar
• Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix((R))): results of two randomized trials. Vaccine 2012; 30:1721-8; PMID:22212127; http://dx.doi.org/10.1016/j.vaccine.2011.12.055
   PubMed Web of Science ®Google Scholar
• Abarca K, Valdivieso F, Potin M, Ibanez I, Vial P. [Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults]. Rev Med Chile 2002; 130:502-10; PMID:12143270; http://dx.doi.org/10.4067/S0034-98872002000500004
   PubMed Web of Science ®Google Scholar
• Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, Poovorawan Y. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003; 21:4194-200; PMID:14505898; http://dx.doi.org/10.1016/S0264-410X(03)00496-1
   PubMed Web of Science ®Google Scholar
• Huang LM, Chang LY, Tang H, Bock HL, Lu CY, Huang FY, Lin TY, Lee CY. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. J Adolesc Health 2005; 37:517; PMID:16310132; http://dx.doi.org/10.1016/j.jadohealth.2005.08.009
   PubMedGoogle Scholar
• Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006; 117:1084-93; PMID:16585302; http://dx.doi.org/10.1542/peds.2005-1759
   PubMed Web of Science ®Google Scholar
• Knuf M, Zepp F, Meyer C, Grzegowski E, Wolter J, Riffelmann M, Wirsing von König CH. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 2006; 24:2043-8; PMID:16356597; http://dx.doi.org/10.1016/j.vaccine.2005.11.024
   PubMed Web of Science ®Google Scholar
• Booy R, Van der Meeren O, Ng SP, Celzo F, Ramakrishnan G, Jacquet JM. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults. Vaccine 2010; 29:45-50; PMID:20974302; http://dx.doi.org/10.1016/j.vaccine.2010.10.025
   PubMed Web of Science ®Google Scholar
• Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009; 27:765-72; PMID:19041352; http://dx.doi.org/10.1016/j.vaccine.2008.11.028
   PubMed Web of Science ®Google Scholar
• Bose A, Dubey AP, Gandhi D, Pandit A, Raghu MB, Raghupathy P, Rao MI, Verghese VP, Datta SK, Bock HL. Safety and reactogenicity of a low dose diphtheria tetanus acellular pertussis vaccine (Boostrix) in pre-school Indian children. Indian Pediatr 2007; 44:421-4; PMID:17620694
   PubMed Web of Science ®Google Scholar
• Zepp F, Habermehl P, Knuf M, Mannhardt-Laakman W, Howe B, Friedland LR. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine 2007; 25:5248-52; PMID:17583395; http://dx.doi.org/10.1016/j.vaccine.2007.05.012
   PubMed Web of Science ®Google Scholar
• Vergara R, Tregnaghi M, Ussher J, Navarro S, Rüttimann R, Potin M, Wolter J, Schuerman L. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 2005; 164:377-82; PMID:15782295; http://dx.doi.org/10.1007/s00431-005-1650-y
   PubMed Web of Science ®Google Scholar
• Weston WM, Chandrashekar V, Friedland LR, Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Human vaccines 2009; 5:858-66; PMID:19838080; http://dx.doi.org/10.4161/hv.9961
   PubMed Web of Science ®Google Scholar
• Sanger R, Behre U, Krause KH, Loch HP, Soemantri P, Herrmann D, Schmitz-Hauss E, Wolter J, Hoet B. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 2007; 166:1229-36; PMID:17235521; http://dx.doi.org/10.1007/s00431-006-0403-x
   PubMedGoogle Scholar